Case Study: Dr Reddy's Labs, Navigating Regulatory Risk in Pharma

Indian pharma stocks can look cheap and steady for years, then lose a fifth of their value on a single regulatory announcement. Dr Reddy's Laboratories is the clearest case study of that risk on NSE. This course starts with how a Hyderabad generic drug maker built a business spanning APIs, US generics and branded emerging markets, and how the USFDA inspection system of Form 483s, warning letters and import alerts works. It then walks through the November 2015 warning letter covering three plants, the share price reaction and the multi-year remediation. From there it widens the lens to patent litigation and at-risk launches, anti-corruption compliance, and the revenue concentration created by a single blockbuster generic. The final chapters turn all of this into a practical investor toolkit: where regulatory signals hide in an annual report, how to value a pharma stock using scenarios instead of a single number, and a checklist you can run on screener.in before buying any Indian pharma company.